ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of “Moderate Buy” from Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has been given an average rating of “Moderate Buy” by the seven analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $18.83.

ALXO has been the subject of several recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a report on Friday, April 12th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of ALX Oncology in a research note on Wednesday, April 10th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $14.00 target price (up from $10.00) on shares of ALX Oncology in a research note on Friday, March 8th.

Insider Buying and Selling at ALX Oncology

In other news, CEO Jason Lettmann purchased 4,400 shares of the stock in a transaction that occurred on Thursday, March 14th. The stock was acquired at an average price of $11.31 per share, with a total value of $49,764.00. Following the purchase, the chief executive officer now owns 171,620 shares in the company, valued at approximately $1,941,022.20. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Jaume Pons sold 50,000 shares of the company’s stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $14.20, for a total value of $710,000.00. Following the completion of the sale, the insider now directly owns 604,205 shares in the company, valued at $8,579,711. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jason Lettmann bought 4,400 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were bought at an average price of $11.31 per share, for a total transaction of $49,764.00. Following the completion of the acquisition, the chief executive officer now owns 171,620 shares of the company’s stock, valued at $1,941,022.20. The disclosure for this purchase can be found here. Company insiders own 50.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Vestal Point Capital LP bought a new stake in ALX Oncology during the fourth quarter worth approximately $24,643,000. TD Asset Management Inc acquired a new position in ALX Oncology in the 4th quarter valued at $1,048,000. Dynamic Technology Lab Private Ltd bought a new position in ALX Oncology in the 4th quarter worth $215,000. Jump Financial LLC acquired a new stake in ALX Oncology in the 4th quarter valued at approximately $371,000. Finally, abrdn plc bought a new position in ALX Oncology in the 4th quarter worth approximately $986,000. Institutional investors and hedge funds own 97.97% of the company’s stock.

ALX Oncology Trading Up 8.9 %

Shares of NASDAQ:ALXO opened at $15.50 on Wednesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 5.24 and a current ratio of 5.24. The stock has a market capitalization of $775 million, a price-to-earnings ratio of -4.13 and a beta of 1.58. ALX Oncology has a 1-year low of $3.94 and a 1-year high of $17.42. The company has a 50 day moving average price of $13.60 and a 200 day moving average price of $12.15.

ALX Oncology (NASDAQ:ALXO) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.09). On average, research analysts anticipate that ALX Oncology will post -3.33 EPS for the current fiscal year.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.